Important Advance Notice: Upcoming Changes to Novo Nordisk Insulin Product Portfolio

Novo Nordisk has advised Medsafe about the planned phase out of Novo Nordisk insulin products, which will occur over the next two years and will focus on older generation products with multiple presentations. This is part of a global insulin portfolio consolidation strategy and is not a result of any safety, efficacy or quality-related concerns.

The table below lists the products and presentations that will be impacted in New Zealand.

We remain committed to working closely with health authorities, the medical community, and patient advocacy groups, in accordance with local regulations, to ensure that patients have access to the medications they need.

We will provide support materials to healthcare professionals to assist patients transitioning to alternative treatments closer to the timings of each product phase-out.